This open, blinded endpoint assessment study will evaluate the activity, safety, tolerability, and pharmacokinetics (PK) of escalating intravenous (IV) doses of AMDX-2011P in CAA subjects. Assessments of retinal images will be conducted by central masked assessors.~To determine the safest dose, participants will receive different amounts of the investigational retinal tracer. The first group of participants taking part in the study will receive a low dose of AMDX-2011P. If no major side effects occur, the dose will be increased for the next group of participants.~Participants will receive a 1 time intravenous injection.~This study plans to enroll up to 20 adult (=/>18 years of age) subjects diagnosed with hereditary CAA or probable or definite CAA according to the modified Boston neuroradiological criteria.
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with cerebral amyloid angiopathy (CAA).